Strand V, Tundia N, Song IH, et al. Early patient-reported outcomes and clinical outcomes with ABT-494 in patients with active rheumatoid arthritis who are inadequate responders to methotrexate or tumor necrosis factor inhibitors: post-hoc analysis of phase 2 randomized controlled trials. EULAR 2017, SAT0217.
Hogere ACR20-respons met olokizumab bij onvoldoende gecontroleerde reumatoïde artritis
aug 2021 | RA